Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242675 | 0.90 | ITGB1 (0.45) | ITGB1ITGA5GPR139MEN1KMT2A | |
| SCHEMBL19426694 | 0.82 | CASR (0.57) | ITGB1ITGA5MEN1KMT2AHTT | |
| SCHEMBL244261 | 0.82 | ITGB3 (0.50) | ITGB1ITGA5GPR139MEN1KMT2A | |
| SCHEMBL19426715 | 0.80 | ITGB1 (0.53) | ITGB1ITGA5GPR139LMNAHTT | |
| SCHEMBL23455386 | 0.79 | ITGB1 (0.64) | ITGB1ITGA5LMNAMAPTSMN1; SMN2 | |
| SCHEMBL23489275 | 0.79 | ITGB1 (0.64) | ITGB1ITGA5LMNAMAPTSMN1; SMN2 | |
| SCHEMBL13082869 | 0.79 | GPR139 (0.43) | ITGB1ITGA5GPR139MEN1KMT2A | |
| SCHEMBL19426623 | 0.78 | ITGB1 (0.47) | ITGB1ITGA5MEN1KMT2ALMNA | |
| SCHEMBL20999272 | 0.78 | ITGB1 (0.47) | ITGB1ITGA5MEN1KMT2ALMNA | |
| SCHEMBL20999541 | 0.78 | ITGB1 (0.54) | ITGB1ITGA5GPR139MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | GENESTE HERVE (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| EP-1239877-B1 | COMPOSITION COMPRISING A TNF-ALPHA INHIBITOR AND AN INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONIST | ABBOTT GMBH & CO KG (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | GENESTE HERVE | 2006-07-20 | — | — | US | disclosed |
| EP-1227847-A2 | INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND ALPHAVBETA3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001024827-A2 | INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | ITGB3, IL6ST, IL1RN | ITGB1 4/4885ITGA5 22/4885GPR139 558/4885 |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | ITGB1 8/4885ITGA5 15/4885GPR139 352/4885 |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | ITGB3, ITGAV, ITGB1 | ITGB1 3/4885ITGA5 20/4885GPR139 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.